Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences has entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate casdatifan in combination with BMS’s investigational bispecific antibody pumitamig. Casdatifan will be added as two new arms to the BMS-sponsored Phase 1/2 ROSETTA RCC-208 trial for advanced renal cell carcinoma, allowing Arcus to generate data on its lead asset in a partner-operationalized setting.
Key figures
- Drug Name
- casdatifan
- Phase Of Trial
- Phase 1/2
- Trial name
- ROSETTA RCC-208
- Partner asset
- pumitamig (BNT327/BMS986545)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.